Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

ABSTRACT: Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

PROVIDER: PRJNA386152 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5525960.fastq.gz	Fastqsanger.gz
	SRR5525970.fastq.gz	Fastqsanger.gz
	SRR5525961.fastq.gz	Fastqsanger.gz
	SRR5525971.fastq.gz	Fastqsanger.gz
	SRR5525962.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 14

Similar Datasets

RNA-seq dataset for Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

Project description:The widespread adoption of transcriptional profiling has led to immense repositories of data that may contain critical insights for developing new therapies. Current approaches to mining these data largely rely on binary classifications of disease versus control. These methods are not able to incorporate measures of disease severity, which are often available. We report an analytical approach to integrate ordinal clinical information with transcriptomics. We have applied this method to public data for a large cohort of Huntington’s disease patients and controls, identifying and prioritizing phenotype-associated genes. To validate the approach, we have performed viability, siRNA knockdown, mRNA-seq, and ChIP-seq on striatal precursor cells expressing either full-length wild type (STHdh Q7) or mutant huntingtin (STHdh Q111). We have verified the role of a high-ranked gene in dysregulation of sphingolipid metabolism in the disease and demonstrated that inhibiting the enzyme, SPL, has neuroprotective effects in HD models. We have shown that one consequence of inhibiting SPL is the intracellular inhibition of HDACs, thus linking our observations in sphingolipid metabolism to a well-characterized HD pathway. Our approach is easily applied to any data with ordinal clinical measurements, and may deepen our understanding of disease processes.

2017-05-11 | GSE98739 | GEO

ChIP-seq dataset for H3K9ac in Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

2017-05-11 | GSE98738 | GEO

Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-05-11 | GSE98740 | GEO

Identifying therapeutic targets by combining transcriptional data with ordinal clinical measurements.

Project description:The immense and growing repositories of transcriptional data may contain critical insights for developing new therapies. Current approaches to mining these data largely rely on binary classifications of disease vs. control, and are not able to incorporate measures of disease severity. We report an analytical approach to integrate ordinal clinical information with transcriptomics. We apply this method to public data for a large cohort of Huntington's disease patients and controls, identifying and prioritizing phenotype-associated genes. We verify the role of a high-ranked gene in dysregulation of sphingolipid metabolism in the disease and demonstrate that inhibiting the enzyme, sphingosine-1-phosphate lyase 1 (SPL), has neuroprotective effects in Huntington's disease models. Finally, we show that one consequence of inhibiting SPL is intracellular inhibition of histone deacetylases, thus linking our observations in sphingolipid metabolism to a well-characterized Huntington's disease pathway. Our approach is easily applied to any data with ordinal clinical measurements, and may deepen our understanding of disease processes.Identifying gene subsets affecting disease phenotypes from transcriptome data is challenge. Here, the authors develop a method that combines transcriptional data with disease ordinal clinical measurements to discover a sphingolipid metabolism regulator involving in Huntington's disease progression.

| S-EPMC5606996 | biostudies-literature

Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers

Project description:Generating automated kidney transplant biopsy reports combining molecular measurements with ensembles of machine learning classifiers

| PRJNA511014 | ENA

Mus musculus

Project description:RNA-seq dataset for Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

| PRJNA386216 | ENA

Identifying biomarkers and therapeutic targets for COPD

Project description:Biological indicator and lung proteomics analyses were performed to identify potential therapeutic targets.

2024-07-27 | PXD054322 |

Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis

Project description:Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosis

| PRJNA604770 | ENA

Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing

Project description:Therapeutic strategy for spinal muscular atrophy by combining gene supplementation and genome editing

| PRJNA854081 | ENA

Mus musculus

Project description:ChIP-seq dataset for H3K9ac in Identifying Novel Therapeutic Targets by Combining Transcriptional Data with Ordinal Clinical Measurements

| PRJNA386217 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data